John Hamer, Ph.D.

Dr. Hamer is Investment Director for Monsanto Growth Ventures, with offices in San Francisco, Boston and St. Louis. Monsanto is the world’s leading agricultural biotechnology company and was recently listed in Forbes magazine as one the World’s Top 10 Most Innovative Companies.

Monsanto Growth Venture, through investment and partnership seeks to foster the growth of an innovation supply chain that includes researchers, entrepreneurs, venture capitalists and emerging high technology companies. Dr. Hamer’s career spans more than three decades of research, senior management and investment experience in the life sciences. Most recently he spent nine years with Burrill & Company, a leading life sciences merchant bank with activities in venture capital, merchant banking and media. Prior to joining Burrill & Company, Dr. Hamer was the CSO and later CEO of Paradigm Genetics/ICORIA, a leading genomics and ag-biotechnology company that completed its IPO on NASDAQ in 2000 and was later acquired by Monsanto.

Dr. Hamer received his Ph. D. in Microbiology from the University of California at Davis and was a Visiting Scientist in Dupont’s Central Research & Development Group. He later joined Purdue University and rose to the rank of full Professor and was the recipient of several national awards including the David Lucille Packard Award, and The National Science Foundation Presidential Faculty Fellowship. At Purdue, Dr. Hamer’s research focused on crop diseases, where he pioneered molecular approaches to disease management and control and worked with numerous international agencies in China, The Philippines and South America.

Dr. Hamer is a passionate believer in new growth opportunity that are emerging in the agricultural value chain in food, health, energy, materials and chemicals.